Main Content

Clinical Research


The survival for childhood cancer has increased from less than 10 percent in the 1950s to more than 80 percent today, with some cancers nearing 100 percent survival. This medical success story was achieved through participation in clinical trials.

The Pediatric Hematology/Oncology faculty and staff are committed to offering enrollment on clinical trials for all pediatric cancer patients for whom a trial is available.

As a member of the Children’s Oncology Group, the Children’s Cancer Center participates in multiple national and international clinical trials. In addition, we partner with pharmaceutical industries to offer additional clinical trials.

Providers also are working with researchers to find new ways to fight childhood cancer, including new combinations of medication, new cancer growth pathways that scientists may target and new ways to ease the after effects of cancer.

Sickle cell research activity

Staff also participate in multiple clinical trials for sickle cell patients.

Dr. Melissa McNaull, associate professor of pediatric hematology and oncology, coordinates work on those trials.

The Children’s Cancer Center offers multiple institutional and multi-center clinical trials, including NIH-sponsored trials and pharmaceutical trials.

The Pediatric Hematology faculty and staff are committed to offering enrollment on clinical trials to all sickle cell disease patients for whom a trial is available.

In addition, UMMC physicians, Dr. Joseph Maher and Dr. Clinton Carroll, working with Dr. Suvankar Majumdar of Children’s National Medical Center, have a National Institutes of Health grant to study the interaction of genetic factors and other factors, present in sickle cell disease, that modify cardiac repolarization and predispose sickle cell patients to heart disease and early mortality.